Similarly, there was no difference in the volume of contrast-enhancing tumour between IDH1-R132H positive and IDH1-R132H negative tumours (10.6 ± 23.9 cm3 vs. 12.1 ± 24.3 cm3; p = NS) and an equal percentage (33%) of IDH1-R132H positive and IDH1-R132H negative tumours demonstrated at least 5 cm3 of contrast-enhancement. Here, IDH1 is linked to neoplasm.